«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2023 01

Page:

74-81

Research Field:

Publishing date:

Info

Title:

Efficacy and safety of chemotherapy combined with PD-1/PD-L1 inhibitors in the treatment of triple-negative breast cancer:A Meta-analysis

Author(s):

ZHAN Xiuzhu¹; CHEN Jun²

1.Clinical Skills Practice Teaching Center,China Medical University,Liaoning Shenyang 110000,China;2.The First Tumor Ward，Shengjing Hospital of China Medical University,Liaoning Shenyang 110000,China.

Keywords:

chemotherapy; PD-1/PD-L1 inhibitors; triple-negative breast cancer; efficacy and safety; Meta-analysis

PACS:

R737.9

DOI:

10.3969/j.issn.1672-4992.2023.01.013

Abstract:

Objective:To evaluate the efficacy and safety of chemotherapy combined with PD-1/PD-L1 inhibitors and chemotherapy alone in the treatment of triple-negative breast cancer by using Meta-analysis,so as to provide guidance for clinical diagnosis and treatment.Methods:Searching Pubmed,Embase,Cochrane Library,CNKI,Wanfang,CQVIP and CBM databases from the establishment of the database to Aug 2021 on the literature on chemotherapy combined with PD-1/PD-L1 inhibitors in the treatment of triple-negative breast cancer.After two researchers independently completed the screening of literature,extracting data,and assessing the risk of bias,RevMan 5.3 software was used for statistical analysis.Results：A total of 8 articles were included in this study.The summary results showed that the OS and PFS of patients in the combination treatment group were significantly longer than those of patients receiving chemotherapy only(HR=0.85,95%CI:0.75~0.96;HR=0.84,95%CI:0.73~0.97).The results also showed that the CRR of patients in the combination therapy group was also significantly higher than that of patients receiving chemotherapy only(RR=1.44,95%CI:1.10~1.89).In addition,the incidence of adverse events in the combined treatment group was higher than that in the chemotherapy alone group(RR=1.08,95%CI:1.03~1.14).The results of the subgroup analysis showed that the OS of patients receiving atezolizumab combined with chemotherapy was significantly longer than that of patients receiving chemotherapy alone(HR=0.85,95%CI:0.75~0.96).In addition,the combination therapy of atezolizumab or pembrolizumab and chemotherapy significantly prolonged the patient's PFS(HR=0.80,95%CI:0.73~0.89;HR=0.79,95%CI:0.67~0.92).However,there was no significant difference in OS and PFS in patients receiving durvalumab combined with chemotherapy compared with chemotherapy alone.Conclusion:These results indicate that chemotherapy combined with PD-1/PD-L1 inhibitors is more effective in the treatment of triple-negative breast cancer than chemotherapy alone,but the combination therapy has a higher incidence of adverse reactions,which deserves our attention.In addition,the combination of durvalumab and chemotherapeutics did not increase the patient's OS and PFS.

References:

[1]JAIN V,KUMAR H,ANOD HV,et al.A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer［J］.J Control Release,2020,326:628-647.
[2］BONOTTO M,GERRATANA L,POLETTO E,et al.Measures of outcome in metastatic breast cancer:insights from a real-world scenario［J］.Oncologist,2014,19(6):608-615.
[3］HAHNEN E,LEDERER B,HAUKE J,et al.Germline mutation status,pathological complete response,and disease-free survival in triple-negative breast cancer:Secondary analysis of the geparsixto randomized clinical trial［J］.JAMA Oncol,2017,3(10):1378-1385.
[4］ADAMS S,GOLDSTEIN LJ,SPARANO JA,et al.Tumor infiltrating lymphocytes(TILs) improve prognosis in patients with triple negative breast cancer(TNBC) ［J］.Oncoimmunology,2015,4(9):e985930.
[5］DENKERT C,MINCKWITZ GV,ESFAHANI SD,et al.Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer:a pooled analysis of 3771 patients treated with neoadjuvant therapy［J］.Lancet Oncol,2018,19(1):40-50.
[6］DENKERT C,MINCKWITZ GV,BRASE JC,et al.Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers［J］.J Clin Oncol,2015,33(9):983-991.
[7］CHAE YK,ARYA A,IAMS W,et al.Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer;lessons learned from clinical trials with melanoma and non-small cell lung cancer(NSCLC) ［J］.J Immunother Cancer,2018,6(1):39.
[8］SCHMID P,ADAMS S,RUGO HS,et al.Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer［J］.N Engl J Med,2018,372(22):2108-2121.
[9］ADAMS S,LOI S,TOPPMEYER D,et al.Pembrolizumab monotherapy for previously untreated,PD-L1-positive,metastatic triple-negative breast cancer:cohort B of the phase II KEYNOTE-086 study［J］.Ann Oncol,2019,30(3):405-411.
[10］SABATIER R,FINETTI P,MAMESSIER E,et al.Prognostic and predictive value of PDL1 expression in breast cancer［J］.Oncotarget,2015,6(7):5449-5464.
[11］MOHER D,LIBERATI A,TETZLAFF J,et al.Preferred reporting items for systematic reviews and meta-analyses:the PRISMA statement［J］.PLoS Med,2009,6(7):e1000097.
[12］SCHMID P,RUGO HS,ADAMS S,et al.Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable,locally advanced or metastatic triple-negative breast cancer(IMpassion130):updated efficacy results from a randomised,double-blind,placebo-controlled,phase 3 trial［J］.Lancet Oncol,2020,21(1):44-59.
[13］NANDA R,LIU MC,YAU C,et al.Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer:An analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial［J］.JAMA Oncol,2020,6(5):676-684.
[14］MITTENDORF EA,ZHANG H,BARRIOS CH,et al.Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer(IMpassion031):a randomised,double-blind,phase 3 trial［J］.Lancet,2020,396(10257):1090-1100.
[15］CORTES J,CESCON DW,RUGO HS,et al.Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer(KEYNOTE-355):a randomised,placebo-controlled,double-blind,phase 3 clinical trial［J］.Lancet,2020,396(10265):1817-1828.
[16］LOIBL S,UNTCH M,BURCHARDI N,et al.A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer:clinical results and biomarker analysis of GeparNuevo study［J］.Ann Oncol,2019,30(8):1279-1288.
[17］SCHMID P,ADAMS S,RUGO HS,et al.Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer［J］.N Engl J Med,2018,379(22):2108-2121.
[18］SCHMID P,CORTES J,PUSZTAI L,et al.Pembrolizumab for early triple-negative breast cancer［J］.N Engl J Med,2020,382(9):810-821.
[19］BACHELOT T,FILLERON T,BIECHE I,et al.Durvalumab compared to maintenance chemotherapy in metastatic breast cancer:the randomized phase II SAFIR02-BREAST IMMUNO trial［J］.Nat Med,2021,27(2):250-255.
[20］DENT R,HANNA WM,TRUDEAU M,et al.Pattern of metastatic spread in triple-negative breast cancer［J］.Breast Cancer Res Treat,2009,115(2):423-428.
[21］KASSAM F,ENRIGHT K,DENT R,et al.Survival outcomes for patients with metastatic triple-negative breast cancer:implications for clinical practice and trial design［J］.Clin Breast Cancer,2009,9(1):29-33.
[22］GUCALP A,TRAINA TA.Triple-negative breast cancer:adjuvant therapeutic options［J］.Chemother Res Pract,2011,2011:1-13.
[23］ARNEDOS M,BIHAN C,DELALOGE S,et al.Triple-negative breast cancer:are we making headway at least［J］.Ther Adv Med Oncol,2012,4(4):195-210.
[24］DISIS ML.Immune regulation of cancer［J］.J Clin Oncol,2010,28(29):4531-4538.
[25］KEIR ME,BUTTE MJ,FREEMAN GJ,et al.PD-1 and its ligands in tolerance and immunity［J］.Annu Rev Immunol,2008,26:677-704.
[26］STERNSCHUSS M,YERUSHALMI R,SALEH RR,et al.Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer:a systematic review and meta-analysis［J］.J Cancer Res Clin Oncol,2021,147(11):3369-3379.
[27］HU XC,HUANG W,FAN M.Emerging therapies for breast cancer［J］.J Hematol Oncol,2017,10(1):98.

Memo

Memo:

-

Common functions

Last Update: 2022-11-30